Castrate Resistant Prostate Cancer Market By Drug Class (Androgen Receptor (AR) Inhibitors, CYP17 Inhibitors, Chemotherapy Agents, Immunotherapy Agents, Radiopharmaceuticals, Others), By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By End-User (Hospitals, Specialty Clinics, Homecare), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Dec 2024 | Report ID: MI1562 | 230 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Drug Class

  • Androgen Receptor (AR) Inhibitors
  • CYP17 Inhibitors
  • Chemotherapy Agents
  • Immunotherapy Agents
  • Radiopharmaceuticals
  • Other

By Therapy Type

  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

List of Companies:

  • Johnson & Johnson
  • Astellas Pharma
  • Sanofi
  • Bayer
  • Pfizer
  • AstraZeneca
  • Novartis
  • Merck & Co.
  • Bristol-Myers Squibb
  • Ipsen
  • Eli Lilly and Co.
  • Amgen
  • AbbVie
  • Takeda Pharmaceutical Company
  • OncoOne
  • Clovis Oncology
  • Bayer HealthCare Pharmaceuticals
  • Roche
  • Exelixis

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing